Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Design, synthesis, and biological evaluation of Osimertinib-Cy7 (OSA-Cy7) conjugate as potential theranostic agent targeting activating EGFR mutations.

BMC biotechnology - 26 Aug 2025

Dong Ying, Li Jinhang, Wu Jia, Huang Lu, Li Xiaoqiong, Zhang Qiaoxuan, Huang Xianzhang, Zhang Pengwei

Abstract excerpt

Accurately predicting the therapeutic response of non-small cell lung cancer (NSCLC) patients to tyrosine kinase inhibitors (TKIs) is of significant clinical importance. The use of TKIs in clinical is primarily guided by the detection of EGFR gene mutations. However, the current EGFR mutation assays face challenges such as inconsistent correlation with therapeutic outcomes, inconvenient sample availability and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbocyanines

Share to Carcinoma, Non-Small-Cell Lung

Share to Drug Design

Share to Indoles

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 40855276
DOI: 10.1186/s12896-025-01025-w
PMCID: PMC12379436

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Design, synthesis, and biological evaluation of Osimertinib-Cy7 (OSA-Cy7) conjugate as potential theranostic agent targeting activating EGFR mutations.PMID 40855276Read ↗

Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo.Semantic proximity Read ↗

Modification of osimertinib to discover new potent EGFRC797S-TK inhibitors.Semantic proximity Read ↗

The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.Semantic proximity Read ↗

Endostar overcomes Osimertinib-resistance mediated EGFR-activation mutation, T790M and cis-C797S triple mutations via enhancing the binding of Osimertinib to EGFR protein.Semantic proximity Read ↗

Design and Evaluation of EGFR-Targeted Near-Infrared Fluorescent Probes for Selective Tumor Cell ImagingSemantic proximity Read ↗

Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Cudratricusxanthone A Exhibits Antitumor Activities Against NSCLC Harboring EGFR L792H and G796R Triple Mutations via Regulating EGFR-ERK/AKT/STAT3 Signaling.Semantic proximity Read ↗

Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib.Semantic proximity Read ↗

HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations.Semantic proximity Read ↗

CZC54252 overcomes Osimertinib resistance by targeting EGFRC797S mutations.Semantic proximity Read ↗

Structure-guided discovery of a potent 2-aryl-4-aminoquinazoline-based inhibitor overcoming osimertinib resistance driven by EGFR C797S mutation in NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.